logo
Acupressure Points for Toothaches

Acupressure Points for Toothaches

Health Line21-07-2025
Acupressure points like Gallbladder 21 (GB21) and Small intestine 18 (SI18) are believed to relieve toothache pain. Other points may help with facial pain or promote relaxation.
Acupressure has been practiced for more than 2,000 years. Many people advocate its effectiveness in soothing muscle aches and pains. Some research suggests that applying pressure to acupressure points may also relieve tooth pain during dental procedures.
Toothache pain requires treatment by a dentist. Untreated, specific underlying causes of tooth pain can get worse. But if you're looking for relief while waiting for your appointment or during a dental procedure, stimulating acupoints may help as a complementary therapy.
Acupressure is a natural, holistic form of Chinese traditional medicine that involves applying pressure to a certain point on the body. The pressure signals the body to relieve tension, remedy blood flow issues, and reduce pain. It can be done by self-massage, by a professional, or by a friend.
However, acupressure is not a substitute for dental care.
Keep reading to learn how to perform acupressure and the specific points that may help relieve toothache pain.
How do I do acupressure?
Acupressure can be administered at home or in an acupressure therapy facility. If you choose your home, pick a quiet, non-stressful area of your living space to help you focus and maximize the benefits of acupressure.
Get into a comfortable position.
Breathe deeply and try to relax your muscles and limbs.
Massage or rub each point with firm pressure.
Repeat as often as you like.
Make sure to stop if intense pain occurs.
Trigger finger 4 (TF4) for toothaches
The trigger finger 4 acupressure point, also known as Shenmen or 'Heavenly Gate,' may be beneficial for tooth pain, according to a 2022 study.
It's located on the top of the ear in the middle of a depression.
Small intestine 18 (SI18) for toothaches
The Small intestine 18 acupressure point, also known as Quanliao, is widely used to relieve pain associated with:
toothaches
swollen gums
tooth decay
It's found perpendicular to the outside of your eye and the outside of your nose, under the cheekbone. It's typically called the cheekbone crevice.
To find it, draw a line directly from the outer corner of your eye down to the hollow of your cheekbone.
Gallbladder 21 (GB21) for facial pain
The Gallbladder 21 point, also known as Jianjing, is often used for:
facial pain
neck pain
headaches
It's located at the top of your shoulders, one on each side. It's right in the middle of the end of your shoulder and the side of your neck.
Practitioners recommend not using the Jianjing acupressure point if you are pregnant, as it may potentially be implicated in inducing labor.
Large intestine 14 (LI4) for above-the-neck pain
The Large intestine 14 point, also known as He Gu, is used for:
headaches
stress
other pains above the neck
You can find it between your thumb and index finger. You can find it by resting your thumb beside the second knuckle of your index finger. The apple (highest point) of the muscle is where LI4 is located.
Chinese medicine practitioners recommend not using the He gu acupressure point if you are pregnant, as it may potentially be implicated in inducing labor.
Stomach 6 (ST6) for mouth and tooth ailments
Stomach 6, also known as Jiache, is typically used to relieve mouth and tooth ailments, particularly those that affect the jaw.
This point is halfway between the corner of your mouth and the bottom of your earlobe.
To find it, clench your teeth together naturally. It's located halfway between the corner of your mouth and the bottom of your earlobe. It's the muscle that flexes when you press your teeth together.
Stomach 36 (ST36) for stress
The Stomach 36 acupressure point, also known as Zusanli or Leg Three Miles, is typically stimulated to relieve:
nausea
tiredness
stress
It is located below your knee. If you place your hand on your kneecap, it's typically where your pinky is resting. You should apply pressure in a downward motion to the outside of your shin bone.
Extra points on the head and neck 1 (EXHN1) for pain
The EXHN1 acupressure points, also known as Sishencong, are believed to relieve head pain, including tension-type headaches.
A 2023 experimental study suggests that acupressure at this point reduced pain during IANB injection in 5- to 10-year-olds and can be used along with conventional measures like topical anesthesia to reduce pain.
It is a group of four points at the vertex of the head around Bai Hu (GV20), in front of, behind, and to either side of GV20.
Extra points on the head and neck 3 (EXHN3) for relaxation
The EXHN3 acupressure point, also known as Yintang or the Hall of Impression, is associated with mental stability and relaxation.
A 2022 clinical trial in children undergoing a dental procedure suggests that stimulating this acupressure point before the procedure may lower heart rate, a potential indicator of anxiety.
It is located in the center of the forehead between the eyebrows.
When to contact a doctor
Acupressure should not be used in place of a visit to a dentist or doctor.
However, it can help provide temporary pain relief along with traditional treatments for toothaches, like pain relievers, until you can schedule a dentist or doctor's appointment.
You should contact your doctor if:
your pain is worsening or unbearable
you have a fever
you have swelling in your mouth, face, or neck
you're experiencing difficulty swallowing or breathing
you're bleeding from the mouth
»FIND CARE: Find a dentist in your area today.
Potential risks of acupressure
Acupressure is generally viewed as safe.
However, if you experience worsening pain while stimulating acupressure points, do not continue. Acupressure should not hurt. If you are in pain while performing acupressure, talk with a doctor.
You should also talk with a doctor before performing acupressure if you are pregnant or have chronic health conditions.
People who are pregnant should not stimulate Jianjing (GB21) or He gu (LI4), as they have the potential to induce labor.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dr. Adam J. Schell Opens Nebraska Spine + Pain Center Satellite Clinic at CHI Health St. Mary's in Nebraska City
Dr. Adam J. Schell Opens Nebraska Spine + Pain Center Satellite Clinic at CHI Health St. Mary's in Nebraska City

Yahoo

time5 minutes ago

  • Yahoo

Dr. Adam J. Schell Opens Nebraska Spine + Pain Center Satellite Clinic at CHI Health St. Mary's in Nebraska City

OMAHA, Neb., July 31, 2025 /PRNewswire/ -- Nebraska Spine + Pain Center is pleased to announce that board-certified orthopedic spine surgeon Dr. Adam J. Schell opens a new satellite clinic on August 12th, 2025. The new clinic is located inside of CHI Health St. Mary's, located at 1301 Grundman Boulevard, Nebraska City, Nebraska 68410. Dr. Schell brings over a decade of expertise specializing in both surgical and nonsurgical treatment for spinal disorders including stenosis, scoliosis, pinched nerves, herniated disks, and spinal trauma. His care philosophy focuses on customized, evidence-based approaches designed to relieve pain and restore function. "I am honored to expand my practice into Nebraska City," said Dr. Schell. "This satellite clinic enables us to better serve patients in the region, offering comprehensive spine care closer to home." The clinic offers full-service spine care, including consultations, diagnostics, and treatment planning. Patients benefit from state-of-the-art onsite imaging (X-ray, CT, MRI) and personalized care plans delivered in partnership with local providers. About Nebraska Spine + Pain Center Nebraska Spine + Pain Center offers comprehensive, multidisciplinary care for pain in the neck and back throughout Nebraska and western Iowa. Nebraska Spine + Pain Center is the region's leading spine health network, delivering comprehensive care with a team of fellowship-trained physicians and specialists. For appointments or referrals:Contact Nebraska Spine + Pain Center at (402) 496‑0404 or request an appointment online at Media Contact:Zach PetersMarketing CoordinatorNebraska Spine + Pain CenterPhone: (402) 496-0404Email: zpeters@ View original content to download multimedia: SOURCE Nebraska Spine + Pain Center Sign in to access your portfolio

‘Japanese Walking' Is a Fitness Trend Worth Trying
‘Japanese Walking' Is a Fitness Trend Worth Trying

New York Times

time37 minutes ago

  • New York Times

‘Japanese Walking' Is a Fitness Trend Worth Trying

Going for a walk is one of the simplest workouts, but it can have powerful health impacts. Walking has been linked to improved mental and cardiovascular health, and it can be effective for managing back pain. But not all walking is equally effective. A method nicknamed 'Japanese walking' on social media — also known as interval walking training, or I.W.T. — seems to offer greater advantages than a simple stroll, or even than walking at a moderate pace for 8,000 or more steps a day. The strategy was first introduced two decades ago in a study led by Hiroshi Nose, an exercise physiologist at Shinshu University Graduate School of Medicine in Japan. The country has one of the world's oldest populations, and Dr. Nose hoped that, by applying interval-training techniques used by elite athletes to its senior community, he could improve older people's health and reduce the country's medical costs, he told The New York Times in an email. After seeing promising early results, he and his collaborator, Shizue Masuki, continued to study the method in depth. While this type of exercise isn't new, it has been a trend on TikTok this summer. Here's what the science says about the benefits of interval walking and how to get started. What is 'Japanese walking'? As the name suggests, interval walking is a form of interval training, which involves alternating between bursts of intense activity and more gentle movement or rest. In this case, it's basically just alternating between fast and slow walking. But compared with more classic forms of high-intensity interval training, interval walking is more approachable for many people, especially those who haven't exercised in a while or who are recovering from injuries that make high-impact activities like running difficult, said Dr. Carlin Senter, the chief of primary-care sports medicine at the University of California, San Francisco. Want all of The Times? Subscribe.

Mezzion Pharmaceuticals Reaches Key Enrollment Milestone in World's Largest Fontan Clinical Trial
Mezzion Pharmaceuticals Reaches Key Enrollment Milestone in World's Largest Fontan Clinical Trial

Yahoo

time4 hours ago

  • Yahoo

Mezzion Pharmaceuticals Reaches Key Enrollment Milestone in World's Largest Fontan Clinical Trial

SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- Mezzion Pharmaceuticals, Inc. (Mezzion) announced that its confirmatory Phase 3 FUEL-2 study evaluating JURVIGO® (udenafil)1 in adolescents and young adults with Fontan circulation has surpassed a key enrollment milestone randomizing approximately 50% of the planned 400+ participants. FUEL-2 is the largest randomized clinical trial ever conducted for the Fontan population, a group of patients born with single ventricle congenital heart disease who require a series of surgeries culminating in the Fontan procedure. This population remains at high risk for heart failure, organ dysfunction, and early mortality, with no FDA-approved pharmacologic therapies available today. "The Fontan journey is long, complex, and often isolating," said Dr. Rahul Rathod, Global Principal Investigator for FUEL-2 and Director of the Single Ventricle Program at Boston Children's Hospital. "With FUEL-2, we're doing more than just advancing a treatment – we're building hope, community, and scientific clarity around a disease that has gone too long without answers." Udenafil, a highly selective and long-acting PDE5 inhibitor, has demonstrated its clinical benefit in Fontan patients with reduced functional capacity (peak VO₂ < 80% of predicted). In the original FUEL trial, this subgroup experienced the most pronounced improvements, particularly in submaximal exercise measures such as ventilatory efficiency and anaerobic threshold – indicators closely tied to functional status in daily life. These findings, combined with FDA-aligned guidance and a growing body of published evidence, informed the focused enrollment criteria for FUEL-2, which is evaluating udenafil exclusively in this higher-risk population. Udenafil has been shown to be safe and well tolerated across more than five years of cumulative exposure, including long-term use in a diverse group of adolescents and young adults from the FUEL trial's open-label extension. In FUEL-2, the primary efficacy endpoint is the change in peak VO2 (mL/kg/min) following 26 weeks of treatment. Peak VO₂ is a validated surrogate for major clinical outcomes, including hospitalization, transplant, and mortality, and a 10% decline is associated with nearly double the risk of death or transplant in Fontan patients.2 "We believe every child and young adult living with Fontan circulation deserves a future with better options," said Dong Hyun 'Dean' Park, Chairman and CEO of Mezzion. "FUEL-2 reflects our deep commitment not only to science but also to the families, clinicians, and advocates who have helped bring this vision to life." To ensure the highest data quality, all cardiopulmonary exercise testing (CPET) in FUEL-2 is centrally reviewed by The Lundquist Institute, an internationally recognized leader in cardiopulmonary diagnostics. This centralized approach enhances consistency and precision in measuring both primary and secondary endpoints across all global sites. FUEL-2 is being conducted at more than 30 of the world's leading children's hospitals across the United States and South Korea. The trial is supported by a global coalition of patient advocacy organizations, clinical investigators, and families dedicated to improving long-term outcomes for individuals with Fontan circulation. Join the Movement Patients and families interested in learning more or joining the study can visit or speak with their care team at a participating center. Clinical sites and investigators are encouraged to continue building on this momentum as we enter the second half of enrollment. Your partnership is critical to delivering the first potential FDA-approved therapy for this vulnerable and resilient community. About Mezzion Mezzion Pharmaceuticals, Inc., a U.S.-based subsidiary of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), is a late-stage biopharmaceutical company focused on developing life-changing therapies for patients with rare and underserved diseases. Headquartered in New Jersey, Mezzion leads the global clinical development and commercialization of JURVIGO® (udenafil), an investigational therapy currently in Phase 3 trials for patients with single ventricle heart disease and Fontan physiology. The company has received Rare Pediatric Disease Designation from the U.S. FDA and anticipates submitting a New Drug Application (NDA) following completion of the FUEL-2 trial. For more information, visit and ¹ JURVIGO® (udenafil) is an investigational drug and has not been approved for the treatment of Fontan patients by the U.S. FDA or any other regulatory authority. The safety and efficacy of JURVIGO® in this population have not been established. 2 Cunningham JW, Nathan AS, Rhodes J, Shafer K, Landzberg MJ, Opotowsky AR. Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation. Am Heart J. 2017;189:184–192. Media Contacts: John Presser, EVP, CBO: Sung-Il Noh, CFO: View original content to download multimedia: SOURCE Mezzion Pharmaceuticals, Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store